• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TCT 2012 UPDATE: St. Jude Medical ticks up on positive PressureWire data

TCT 2012 UPDATE: St. Jude Medical ticks up on positive PressureWire data

October 24, 2012 By MassDevice staff

St. Jude Medical's Fame II FFR study

Results from the Fame II study comparing St. Jude Medical‘s (NYSE:STJ) PressureWire fractional flow reserve device with optimal medical care show that FFR-guided coronary interventions are more cost-effective, sending STJ shares up nearly 2% today on Wall Street.

The St. Paul, Minn.-based medical device company funded the trial, which earlier this year demonstrated that the FFR-guided PCI arm patients fared better than the control arm. Now the company said the data also show that the procedure is less expensive than medical therapy alone over the long term.

Dr. William Fearon of Stanford University, presenting data at the Transcatheter Cardiovascular Therapeutics conference today in Miami, said that the previous Courage trial influences cardiologists to let optimal medical therapy run its course before attempting PCI, according to heartwire.

"Based on Courage, people have argued that up-front optimal medical therapy should be achieved before proceeding to PCI, but what we showed in FAME II was that if you can identify ischemia-producing lesions and isolate those, patients [with those lesions] benefit from PCI up front as compared with optimal medical therapy, by decreasing urgent revascularization and improving quality of life," Fearon said, according to the website.

During the 1st year, optimal medical therapy costs about $2,508 less than FFR-guided PCI. But reduced incidence of angina and urgent revascularization make FFR-guided PCI more cost-effective over time. Angiography-guided PCI posted a cost-effectiveness ratio of $168,000 per quality-adjusted life-year; for FFR-guided PCI in Fame II, that number was $53,000 – comparable to other widely accepted therapies, Fearon said.

"We want to be conservative and not overstate things," he said, according to heartwire. "We don’t have longer follow-up at this time, but … the benefit of PCI lasted more than 1 year in Courage, and freedom from angina [in the PCI group] lasted out to 3 years."

"While FFR-guided PCI had a higher initial cost than patients treated by medical therapy alone, after 1 year the cost gap narrowed by more than 50% due to a higher number of hospital re-admissions for patients treated only with medical therapy," St. Jude Medical said in a press release.

The news sent STJ shares up 1.6% to a $39.71 close today. Shares were up slightly at $39.73 in after-hours trading.

"While FFR-guided PCI had a higher initial cost than patients treated by medical therapy alone, after 1 year the cost gap narrowed by more than 50% due to a higher number of hospital re-admissions for patients treated only with medical therapy," according to the release.

Early this year, St. Jude cut short the Fame II study due after an interim analysis showed that 11.1% of the optimal-medical-management arm needed urgent revascularization, compared with 1.6% of the PCI cohort, according to heartwire.

The shortened duration of the study poses a problem for skeptics including Dr. William Boden, who wrote an editorial for the New England Journal of Medicine, "What is More Enduring – Fame or Courage?," questioning the study’s validity due to its shortened term.

"Clearly, FFR holds potential promise for a more targeted approach to PCI that might be more clinically effective and cost-effective than visually directed PCI for all angiographically significant stenoses," Boden wrote. "Unfortunately, the early termination of the FAME II trial before full enrollment and follow-up were achieved, the neutral effects on the rate of death or myocardial infarction, and the lack of a significant, sustained treatment effect on the reduction of angina beyond 6 months leave more questions than answers."

The Fame II study proved to be important, not just for St. Jude, but for FFR rival Volcano Corp. (NSDQ:VOLC). Those companies are embroiled in a bitter patent dispute over FFR technology. The study could also help boost the sagging stents businesses of the major players in the market, Boston Scientific (NYSE:BSX), Abbott (NYSE:ABT) and Medtronic (NYSE:MDT).

Filed Under: News Well Tagged With: stjudemedical, TCT 2012, Transcatheter Cardiovascular Therapeutics symposium (TCT)

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy